Floatz logo

Bendamustine

Head and Neck Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

37 Active assets in the Head and Neck Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
National Cancer Institute (NCI)
Phase 2BB
Tadalafil
University of California, San Diego
Phase 2B
su011248
National Cancer Institute (NCI)
Phase 2CCC
Ulixertinib
National Cancer Institute (NCI)
Phase 2CCC
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493
National Cancer Institute (NCI)
Phase 2CCC

View all 43 →

Same molecule, other indications

Bendamustine is also rated in:

mantle cell lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →